ADC Therapeutics (ADCT) Total Non-Current Liabilities (2019 - 2026)

ADC Therapeutics (ADCT) has reported Total Non-Current Liabilities for 8 consecutive years, with $203.2 million the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 10.45% year-over-year to $203.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $203.2 million (up 10.45% YoY) and the FY2025 annual result came in at $186.5 million, down 8.83% from the prior year.
• Total Non-Current Liabilities grew to $203.2 million in Q1 2026 per ADCT's latest filing, from $186.5 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for ADCT reached as high as $442.9 million in Q3 2023 and fell as low as $184.0 million in Q1 2025.
• A 5-year average of $265.8 million and a median of $203.2 million in 2026 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 184.82% — and 2024, when it tumbled 56.99%.
• Year by year, Total Non-Current Liabilities stood at $341.5 million in 2022, then plunged by 41.59% to $199.5 million in 2023, then advanced by 2.54% to $204.5 million in 2024, then declined by 8.83% to $186.5 million in 2025, then gained by 8.97% to $203.2 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $203.2 million, $186.5 million, and $187.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.